The global varicella attenuated live vaccine market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 1.2 billion by 2030. The market is driven by factors such as increasing awareness about the disease and its complications, growing number of cases in children and adults, and availability of vaccines with improved efficacy.
Monovalent Vaccine: The monovalent vaccine segment accounted for the largest share in 2018 due to its high demand among kids injection application segment. Combination Vaccine: The combination vaccine segment is expected to grow at a higher CAGR during the forecast period due to its high demand among adults injection application segment. Kids Injection: Kids injection application accounted for the largest share in 2018 due to increasing awareness about varicella infection among parents and pediatricians which leads them towards vaccination against it. Adults Injection: Adults injection application accounted for the second-largest share in 2018 due to increased incidence rates of varicella infection among adults which leads them towards vaccination against it.
- Varicella is a highly contagious disease that can be fatal in some cases.
- The vaccine is recommended for children 12 months of age and older, adolescents, and adults who have not been vaccinated or who have not had chickenpox.
- The vaccine is given as a single injection to the upper arm or thigh muscle and provides protection against chickenpox for about 3 years after vaccination.
- Vaccination with the varicella vaccine reduces the risk of developing severe complications from chickenpox by 90%.
- In addition to protecting against chickenpox, vaccination also protects against shingles (herpes zoster) later in life.
Industry Growth Insights published a new data on “Varicella Attenuated Live Vaccine Market”. The research report is titled “Varicella Attenuated Live Vaccine Market research by Types (Monovalent Vaccine, Combination Vaccine), By Applications (Kids Injection, Adults Injection), By Players/Companies Merck, GSK, BCHT, Changsheng, Keygen, Green Cross, Biken”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Varicella Attenuated Live Vaccine Market Research Report
By Type
Monovalent Vaccine, Combination Vaccine
By Application
Kids Injection, Adults Injection
By Companies
Merck, GSK, BCHT, Changsheng, Keygen, Green Cross, Biken
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Varicella Attenuated Live Vaccine Market Report Segments:
The global Varicella Attenuated Live Vaccine market is segmented on the basis of:
Types
Monovalent Vaccine, Combination Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Kids Injection, Adults Injection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- GSK
- BCHT
- Changsheng
- Keygen
- Green Cross
- Biken
Highlights of The Varicella Attenuated Live Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monovalent Vaccine
- Combination Vaccine
- By Application:
- Kids Injection
- Adults Injection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Varicella Attenuated Live Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Varicella Attenuated Live Vaccine (Vax-Polio) is a vaccine that helps protect people from Varicella, a virus that can cause chickenpox. Vax-Polio is made from the same viruses used to make other vaccines, but has been weakened so it does not cause serious health problems. It is given as an injection into the arm.
Some of the major companies in the varicella attenuated live vaccine market are Merck, GSK, BCHT, Changsheng, Keygen, Green Cross, Biken.
The varicella attenuated live vaccine market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Varicella Attenuated Live Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Varicella Attenuated Live Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Varicella Attenuated Live Vaccine Market - Supply Chain
4.5. Global Varicella Attenuated Live Vaccine Market Forecast
4.5.1. Varicella Attenuated Live Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Varicella Attenuated Live Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Varicella Attenuated Live Vaccine Market Absolute $ Opportunity
5. Global Varicella Attenuated Live Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Type
5.3.1. Monovalent Vaccine
5.3.2. Combination Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Varicella Attenuated Live Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Application
6.3.1. Kids Injection
6.3.2. Adults Injection
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Varicella Attenuated Live Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Varicella Attenuated Live Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Varicella Attenuated Live Vaccine Demand Share Forecast, 2019-2026
9. North America Varicella Attenuated Live Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Application
9.4.1. Kids Injection
9.4.2. Adults Injection
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Type
9.7.1. Monovalent Vaccine
9.7.2. Combination Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Varicella Attenuated Live Vaccine Demand Share Forecast, 2019-2026
10. Latin America Varicella Attenuated Live Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Application
10.4.1. Kids Injection
10.4.2. Adults Injection
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Type
10.7.1. Monovalent Vaccine
10.7.2. Combination Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Varicella Attenuated Live Vaccine Demand Share Forecast, 2019-2026
11. Europe Varicella Attenuated Live Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Application
11.4.1. Kids Injection
11.4.2. Adults Injection
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Type
11.7.1. Monovalent Vaccine
11.7.2. Combination Vaccine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Varicella Attenuated Live Vaccine Demand Share, 2019-2026
12. Asia Pacific Varicella Attenuated Live Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Application
12.4.1. Kids Injection
12.4.2. Adults Injection
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Type
12.7.1. Monovalent Vaccine
12.7.2. Combination Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Varicella Attenuated Live Vaccine Demand Share, 2019-2026
13. Middle East & Africa Varicella Attenuated Live Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Application
13.4.1. Kids Injection
13.4.2. Adults Injection
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Varicella Attenuated Live Vaccine Market Size and Volume Forecast by Type
13.7.1. Monovalent Vaccine
13.7.2. Combination Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Varicella Attenuated Live Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Varicella Attenuated Live Vaccine Market: Market Share Analysis
14.2. Varicella Attenuated Live Vaccine Distributors and Customers
14.3. Varicella Attenuated Live Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. BCHT
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Changsheng
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Keygen
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Green Cross
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Biken
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
